

Europe will be the largest medical cannabis market in the world with a market of over 739 million people, and total healthcare spend of €1.49t. Both business and government realize that this

thriving industry has a future but the development of new treatment methods based on cannabinoid medications must be based on conclusive research. A record level of investment in research has been seen in new medical cannabis cultivation facilities opening across Europe. One of the results has been an ever increasing list of predominantly chronic conditions of ageing population that cannabinoid based therapies can treat. As the list grows, so does the potential patient base. Clinical H[SHULHQFH DQG LQLWLDO HYLGHQFH VLJQLÀFDQWO\ indicate needs for personalisation of cannabis WUHDWPHQW ZLWK H+HDOWK WRROV WR SURYLGH HIÀFLHQ cure while keeping the quality of life on ambient level for EU ageing population.

Keywords-Cannabis, Cannabinoid Medication, Ageing Population, Personalisation

Biography

D Y H O . X E X L V W K H H m e d i c a l W L Q  
informatics and adictology In 2001, graduated  
in general medicine with a focus on diseases  
prevention at Charles University in Prague, 3rd  
Medical Faculty. Since 2005 to 2015 worked for  
Intel Corporation as the Business Development  
Manager leading projects of for Healthcare and  
Education in Central and Eastern Europe. In 2006

H[SHULHQFH DQG LQLWLDO HYLGHQFH VLJQLÀFDQWO\  
WUHDWPHQW ZLWK H+HDOWK WRROV WR SURYLGH HIÀFLHQ